Fibroblast Growth Factors Market, By Product (FGF21, FGF7, FGF23, FGF1, FGF10, FGF2, FGF19 and Others), By Product Form, By Application, By End User, By Usage, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
|
Report ID
ANV6180
|
Published Date
October 2026
|
Pages
299
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Fibroblast Growth Factors Market size was valued at US$ 310.6 Million in 2025, expanding at a CAGR of 6.2% from 2026 to 2033.
The Fibroblast Growth Factors (FGFs) refer to the set of secreted proteins which perform a number of biological roles, such as angiogenesis, wound healing and organogenesis, through the activation of cell-surface tyrosine kinase receptors in a manner that is highly context-dependent. The FGF molecules have a typical structure where the trefoil globular domain is responsible for the interaction between the molecule itself and the receptor as well as the heparan sulphate cofactor. The globular domain is followed by the isoform-specific domains whose structure determines the way FGFs affect the receptor signalling and the mode of FGFs\' action (autocrine, paracrine or endocrine signalling). The structure of the FGFs as well as the possible post-translational modifications provides these proteins with a unique property to exert a pleiotropic effect on almost all cell types, including those in cancerous tissue. Hence qualifying them as a candidate for treatment of the disease (oncogenes), regeneration (cell proliferation and differentiation) and metabolic disorders.
Fibroblast Growth Factors Market- Market Dynamics
Advancements In Recombinant Protein Engineering To Boost Market Demand
Advancements in recombinant protein engineering are expected to drive the Fibroblast Growth Factors market forward. The development of recombinant protein engineering in the production of fibroblast growth factors will help increase the production of effective and efficient fibroblasts. This type of technology helps to improve the growth of the cells and tissue, as well as their further treatment and healing, and to improve the quality of the fibroblast products for research and therapeutic purposes. For instance, in May 2026, according to the Recombinant Protein Drugs: A 2025 Update report, there has been progress in recombinant protein therapeutics because of the rapid development in synthetic biology, host cell engineering, and bioprocess optimization; the focus has shifted to bispecific antibodies, nanobodies, fusion proteins, and self-assembling biomaterials and also contains cumulative and yearly biologics approvals by both the U.S. FDA and the European Medicines Agency (EMA), which are based on data until 2025. These advancements are expected to enhance FGF product quality, stability, efficacy, and therapeutic applications.
Fibroblast Growth Factors Market- Segmentation Analysis:
The Global Fibroblast Growth Factors Market is segmented on the basis of Product, Product Form, Application, End User, Usage, and Region.
Under application, wound healing plays a key role because fibroblast growth factors (FGFs) support cell proliferation, cell migration, tube formation, angiogenesis, and tissue regeneration that assist in the quicker healing of a wound and repair of skin and tissues. In April 2025, Thermo Fisher Scientific brought out its range of recombinant fibroblast growth factors and growth hormone based on its FGF-1, FGF-2, FGF-7, and FGF-10 specifically for this use, and it has proved to be extremely important for wound and tissue healing. In the case of the FGF-10 recombinant protein, Thermo Fisher Scientific also mentions its role in wound healing, which is basically wound and tissue repair. This portfolio reinforces Thermo Fisher Scientific’s role in advancing wound healing and tissue repair research applications.
Fibroblast Growth Factors Market- Geographical Insights
North America holds a notable place in the Fibroblast Growth Factors market due to its advanced healthcare sector, developed biotechnology industry, and substantial spending on research and development. For instance, in March 2026, according to the UNESCO (Org.) Institute for Statistics, the global investment in research and development grew from 1.71% to 1.92% of global GDP, while the R&D expenditure percentage of GDP value in Europe and Northern America & Europe reached 2.55%, which is the highest among all the regions. 73% of countries are still spending less than 1% of their GDP on R&D. The importance and value of R&D have grown further, which helps North America in maintaining its position in FGF research and innovation.
India Fibroblast Growth Factors Market - Country Insights
India offers huge potential for growth in this regard due to its large senior citizen population, along with an increase in lifestyle diseases. The demands are driven by the requirement of advanced treatment techniques to manage wounds, regenerative medicine & oncology. In January 2025, according to the NIH Gov report, the prevalence rate of diabetes cases in the country is between 11% and 20% in urban areas and 3% to 10% in rural areas. Some 77 million adults in India have the disease. Nearly 25% of deaths in India are caused by heart disease, and 25% of people over 18 years old suffer from hypertension. About 5% of the Indian population is obese, while 14.4% of all Indian children suffer from the disease. Around 197.3 million of the Indian population suffers from mental disorders. Such health trends among the population are bound to raise the demand for regenerative and advanced wound healing treatments.
Fibroblast Growth Factors Market- Competitive Landscape:
The Fibroblast Growth Factors market is being affected by several companies that are working towards creating further advancements in the area of protein engineering as well as in other biotechnological efforts. Some of the companies which are working towards making such advancements are Lonza Group, FUJIFILM Wako Pure Chemical, Miltenyi Biotec, Akero Therapeutics, and 89Bio Inc. These companies are trying to make advancements in the area of regenerative medicine, manufacturing methods, and treatment therapies in the areas of oncology, wound healing, and cell therapy. In September 2025, Miltenyi Biotec collaborated with Verismo Therapeutics in order to develop STAR-101 through the supply of clinical-grade lentiviral vectors. These strategic advancements are accelerating innovation and expanding therapeutic applications across the FGF market.
Recent Developments:
- In January 2026, FUJIFILM Wako Pure Chemical initiated the manufacture of its GMP CHIR99021 GSK-3β inhibitor on a commercial scale for use in cell culture processes, adding to its range of reagents that facilitate the research and production of cell therapies.
- In September 2025, 89bio signed a merger agreement for acquisition by Roche, integrating Roche\'s development, manufacturing, and marketing capabilities with 89bio\'s pegozafermin, an FGF21 analogue under development for MASH.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL FIBROBLAST GROWTH FACTORS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Thermo Fisher Scientific
- R&D Systems (Bio-Techne)
- Merck KGaA (Sigma-Aldrich)
- Abcam
- Cell Signaling End User
- GenScript Biotech
- Lonza Group
- Miltenyi Biotec
- FUJIFILM Wako Pure Chemical
- MedChemExpress
- Proteintech Group
- Elabscience Biotech
- ACROBiosystems
- STEMCELL Technologies
- Sino Biological
- Creative BioMart
- BioLegend
- Others
GLOBAL FIBROBLAST GR MARKET, BY PRODUCT- MARKET ANALYSIS, 2020 - 2033
- FGF21
- FGF7
- FGF23
- FGF1
- FGF10
- FGF2
- FGF19
- Others
GLOBAL FIBROBLAST GROWTH FACTORS MARKET, BY PRODUCT FORM- MARKET ANALYSIS, 2020 - 2033
- Finished Formulations
- Research Grade
- Kits & Diagnostic Reagents
- GMP Grade
GLOBAL FIBROBLAST GROWTH FACTORS MARKET, BY APPLICATION- MARKET ANALYSIS, 2020 - 2033
- Cell Therapy
- Dermatology
- Oncology
- Cardiovascular Disease & Diabetes
- Wound Healing
- Hematology
- Others
GLOBAL FIBRlOBLAST GROWTH FACTORS MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033
- Contract Research & Manufacturing Organizations
- Pharmaceutical & Biotechnology Companies
- Research Centers & Academic Institutes
- Others
GLOBAL FIBROBLAST GROWTH FACTORS MARKET, BY USAGE- MARKET ANALYSIS, 2020 - 2033
- Topical FGFs
- Clinical-Stage Use
- Implant/Scaffold-Integrated FGFs
- In-Vivo Preclinical Use
- Injectable FGFs
- In-Vitro Use
GLOBAL FIBROBLAST GROWTH FACTORS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
TABLE OF CONTENT
1. Fibroblast Growth Factors Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Fibroblast Growth Factors Market Snippet by Product
2.1.2. Fibroblast Growth Factors Market Snippet by Product Form
2.1.3. Fibroblast Growth Factors Market Snippet by Application
2.1.4. Fibroblast Growth Factors Market Snippet by End User
2.1.5. Fibroblast Growth Factors Market Snippet by Usage
2.1.6. Fibroblast Growth Factors Market Snippet by Country
2.1.7. Fibroblast Growth Factors Market Snippet by Region
2.2. Competitive Insights
3. Fibroblast Growth Factors Key Market Trends
3.1. Fibroblast Growth Factors Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Fibroblast Growth Factors Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Fibroblast Growth Factors Market Opportunities
3.4. Fibroblast Growth Factors Market Future Trends
4. Fibroblast Growth Factors Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Fibroblast Growth Factors Market : Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Fibroblast Growth Factors Market Landscape
6.1. Fibroblast Growth Factors Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Fibroblast Growth Factors Market – By Product
7.1. Overview
7.1.1. Segment Share Analysis, By Product, 2025 & 2033 (%)
7.1.2. FGF21
7.1.3. FGF7
7.1.4. FGF23
7.1.5. FGF1
7.1.6. FGF10
7.1.7. FGF2
7.1.8. FGF19
7.1.9. Others
8. Fibroblast Growth Factors Market – By Product Form
8.1. Overview
8.1.1. Segment Share Analysis, By Product Form, 2025 & 2033 (%)
8.1.2. Finished Formulations
8.1.3. Research Grade
8.1.4. Kits & Diagnostic Reagents
8.1.5. GMP Grade
9. Fibroblast Growth Factors Market – By Application
9.1. Overview
9.1.1. Segment Share Analysis, By Application, 2025 & 2033 (%)
9.1.2. Cell Therapy
9.1.3. Dermatology
9.1.4. Oncology
9.1.5. Cardiovascular Disease & Diabetes
9.1.6. Wound Healing
9.1.7. Hematology
9.1.8. Others
10. Fibroblast Growth Factors Market – By End User
10.1. Overview
10.1.1. Segment Share Analysis, By End User, 2025 & 2033 (%)
10.1.2. Contract Research & Manufacturing Organizations
10.1.3. Pharmaceutical & Biotechnology Companies
10.1.4. Research Centers & Academic Institutes
10.1.5. Others
11. Fibroblast Growth Factors Market – By Usage
11.1. Overview
11.1.1. Segment Share Analysis, By Usage, 2025 & 2033 (%)
11.1.2. Topical FGFs
11.1.3. Clinical-Stage Use
11.1.4. Implant/Scaffold-Integrated FGFs
11.1.5. In-Vivo Preclinical Use
11.1.6. Injectable FGFs
11.1.7. In-Vitro Use
12. Fibroblast Growth Factors Market – By Geography
12.1. Introduction
12.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
12.2. North America
12.2.1. Overview
12.2.2. Fibroblast Growth Factors Key Manufacturers in North America
12.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
12.2.4. North America Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
12.2.5. North America Market Size and Forecast, By Product Form, 2020 - 2033 (US$ Million)
12.2.6. North America Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
12.2.7. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.2.8. North America Market Size and Forecast, By Usage, 2020 - 2033 (US$ Million)
12.2.9. U.S.
12.2.10. Canada
12.3. Europe
12.3.1. Overview
12.3.2. Fibroblast Growth Factors Key Manufacturers in Europe
12.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
12.3.4. Europe Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
12.3.5. Europe Market Size and Forecast, By Product Form, 2020 - 2033 (US$ Million)
12.3.6. Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
12.3.7. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.3.8. Europe Market Size and Forecast, By Usage, 2020 - 2033 (US$ Million)
12.3.9. Germany
12.3.10. UK
12.3.11. France
12.3.12. Italy
12.3.13. Spain
12.3.14. The Netherlands
12.3.15. Sweden
12.3.16. Russia
12.3.17. Poland
12.3.18. Denmark
12.3.19. Rest of Europe
12.4. Asia Pacific (APAC)
12.4.1. Overview
12.4.2. Fibroblast Growth Factors Key Manufacturers in Asia Pacific
12.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
12.4.4. APAC Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
12.4.5. APAC Market Size and Forecast, By Product Form, 2020 - 2033 (US$ Million)
12.4.6. APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
12.4.7. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.4.8. APAC Market Size and Forecast, By Usage, 2020 - 2033 (US$ Million)
12.4.9. China
12.4.10. India
12.4.11. Japan
12.4.12. South Korea
12.4.13. Australia
12.4.14. Indonesia
12.4.15. Thailand
12.4.16. Philippines
12.4.17. Taiwan
12.4.18. Vietnam
12.4.19. Rest of APAC
12.5. Latin America (LATAM)
12.5.1. Overview
12.5.2. Fibroblast Growth Factors Key Manufacturers in Latin America
12.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
12.5.4. LATAM Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
12.5.5. LATAM Market Size and Forecast, By Product Form, 2020 - 2033 (US$ Million)
12.5.6. LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
12.5.7. LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.5.8. LATAM Size and Forecast, By Usage, 2020 - 2033 (US$ Million)
12.5.9. Brazil
12.5.10. Mexico
12.5.11. Argentina
12.5.12. Colombia
12.5.13. Rest of LATAM
12.6. Middle East and Africa
12.6.1. Overview
12.6.2. Fibroblast Growth Factors Key Manufacturers in Middle East and Africa
12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
12.6.4. Middle East and Africa Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
12.6.5. Middle East and Africa Market Size and Forecast, By Product Form, 2020 - 2033 (US$ Million)
12.6.6. Middle East and Africa Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
12.6.7. Middle East and Africa Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12.6.8. Middle East and Africa Market Size and Forecast, By Usage, 2020 - 2033 (US$ Million)
12.6.9. Saudi Arabia
12.6.10. UAE
12.6.11. Israel
12.6.12. Turkey
12.6.13. Algeria
12.6.14. Egypt
12.6.15. Iran
12.6.16. Qatar
12.6.17. Rest of MEA
13. Key Vendor Analysis- Fibroblast Growth Factors Industry
13.1. Competitive Benchmarking
13.1.1. Competitive Dashboard
13.1.2. Competitive Positioning
13.2. Company Profiles
13.2.1. Thermo Fisher Scientific
13.2.2. R&D Systems (Bio-Techne)
13.2.3. Merck KGaA (Sigma-Aldrich)
13.2.4. Abcam
13.2.5. Cell Signaling End User
13.2.6. GenScript Biotech
13.2.7. Lonza Group
13.2.8. Miltenyi Biotec
13.2.9. FUJIFILM Wako Pure Chemical
13.2.10. MedChemExpress
13.2.11. Proteintech Group
13.2.12. Elabscience Biotech
13.2.13. ACROBiosystems
13.2.14. STEMCELL Technologies
13.2.15. Sino Biological
13.2.16. Creative BioMart
13.2.17. BioLegend
13.2.18. Others
14. 360 Degree AnalystView
15. Appendix
15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL FIBROBLAST GROWTH FACTORS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Thermo Fisher Scientific
- R&D Systems (Bio-Techne)
- Merck KGaA (Sigma-Aldrich)
- Abcam
- Cell Signaling End User
- GenScript Biotech
- Lonza Group
- Miltenyi Biotec
- FUJIFILM Wako Pure Chemical
- MedChemExpress
- Proteintech Group
- Elabscience Biotech
- ACROBiosystems
- STEMCELL Technologies
- Sino Biological
- Creative BioMart
- BioLegend
- Others
GLOBAL FIBROBLAST GR MARKET, BY PRODUCT- MARKET ANALYSIS, 2020 - 2033
- FGF21
- FGF7
- FGF23
- FGF1
- FGF10
- FGF2
- FGF19
- Others
GLOBAL FIBROBLAST GROWTH FACTORS MARKET, BY PRODUCT FORM- MARKET ANALYSIS, 2020 - 2033
- Finished Formulations
- Research Grade
- Kits & Diagnostic Reagents
- GMP Grade
GLOBAL FIBROBLAST GROWTH FACTORS MARKET, BY APPLICATION- MARKET ANALYSIS, 2020 - 2033
- Cell Therapy
- Dermatology
- Oncology
- Cardiovascular Disease & Diabetes
- Wound Healing
- Hematology
- Others
GLOBAL FIBRlOBLAST GROWTH FACTORS MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033
- Contract Research & Manufacturing Organizations
- Pharmaceutical & Biotechnology Companies
- Research Centers & Academic Institutes
- Others
GLOBAL FIBROBLAST GROWTH FACTORS MARKET, BY USAGE- MARKET ANALYSIS, 2020 - 2033
- Topical FGFs
- Clinical-Stage Use
- Implant/Scaffold-Integrated FGFs
- In-Vivo Preclinical Use
- Injectable FGFs
- In-Vitro Use
GLOBAL FIBROBLAST GROWTH FACTORS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Analystview Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
